164 related articles for article (PubMed ID: 19438486)
1. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.
Morabito F; Cutrona G; Gentile M; Matis S; Todoerti K; Colombo M; Sonaglio C; Fabris S; Reverberi D; Megna M; Spriano M; Lucia E; Rossi E; Callea V; Mazzone C; Festini G; Zupo S; Molica S; Neri A; Ferrarini M
Br J Haematol; 2009 Jun; 146(1):44-53. PubMed ID: 19438486
[TBL] [Abstract][Full Text] [Related]
2. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
[TBL] [Abstract][Full Text] [Related]
4. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
[TBL] [Abstract][Full Text] [Related]
5. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
6. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC;
Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290
[TBL] [Abstract][Full Text] [Related]
7. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
8. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M
Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778
[TBL] [Abstract][Full Text] [Related]
9. Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
Molica S; Digiesi G; Mirabelli R; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Morabito F; Neri A; Baldini L; Ferrarini M
Eur J Haematol; 2009 Sep; 83(3):208-14. PubMed ID: 19459926
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L
Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928
[TBL] [Abstract][Full Text] [Related]
11. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230
[TBL] [Abstract][Full Text] [Related]
12. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
[TBL] [Abstract][Full Text] [Related]
13. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia.
Del Giudice I; Morilla A; Osuji N; Matutes E; Morilla R; Burford A; Maravelaki S; Owusu-Ankomah K; Swansbury J; A'Hern R; Brito-Babapulle V; Catovsky D
Cancer; 2005 Nov; 104(10):2124-32. PubMed ID: 16211545
[TBL] [Abstract][Full Text] [Related]
14. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
Abousamra NK; El-Din MS; Azmy E
Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
Del Principe MI; Del Poeta G; Venditti A; Buccisano F; Maurillo L; Marini R; Cox MC; Panetta P; Suppo G; Degan M; Bruno A; Gattei V; Amadori S
Haematologica; 2004 Dec; 89(12):1468-75. PubMed ID: 15590397
[TBL] [Abstract][Full Text] [Related]
17. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
[TBL] [Abstract][Full Text] [Related]
18. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients.
Zanotti R; Frattini F; Ghia P; Visco C; Zamò A; Perbellini O; Stella S; Facco M; Giaretta I; Chilosi M; Pizzolo G; Ambrosetti A
Am J Hematol; 2010 Jul; 85(7):494-8. PubMed ID: 20575031
[TBL] [Abstract][Full Text] [Related]
19. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
[TBL] [Abstract][Full Text] [Related]
20. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Sheikholeslami MR; Jilani I; Keating M; Uyeji J; Chen K; Kantarjian H; O'Brien S; Giles F; Albitar M
Cytometry B Clin Cytom; 2006 Jul; 70(4):270-5. PubMed ID: 16906585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
